Gilead Sciences' (GILD) Treatment of Pulmonary Arterial Hypertension Granted Orphan Drug Status by FDA

August 24, 2016 8:29 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Gilead Sciences' (NASDAQ: GILD) treatment of pulmonary arterial hypertension was granted orphan drug status by the FDA. The generic name is ambrisentan/tadalafil fixed combination.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment